regadenoson has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cerqueira, MD; Iskandrian, AE; Nguyen, P; Staehr, P; Underwood, SR | 1 |
| Adluru, G; Chen, L; DiBella, EV; Fluckiger, JU; Jiji, R; Kim, TH; Kuppahally, S; Litwin, SE; Matthews, B; McGann, C; Pack, NA; Priester, T | 1 |
2 trial(s) available for regadenoson and Obesity
| Article | Year |
|---|---|
Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Coronary Circulation; Diabetes Complications; Double-Blind Method; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Obesity; Patient Satisfaction; Predictive Value of Tests; Purines; Pyrazoles; Risk Assessment; Risk Factors; Sex Factors; Tomography, Emission-Computed, Single-Photon | 2008 |
The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adult; Body Mass Index; Contrast Media; Coronary Circulation; Drug Dosage Calculations; Female; Humans; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Magnetic Resonance Imaging, Cine; Male; Meglumine; Middle Aged; Myocardial Perfusion Imaging; Obesity; Organometallic Compounds; Predictive Value of Tests; Purines; Pyrazoles; Time Factors; Utah; Vasodilator Agents | 2012 |